bitBiome’s platform is built on their proprietary single-cell microbial genome analysis technology, bit-MAP®. Using bioinformatics, machine learning and artificial intelligence, bitBiome has used bit-MAP to create a comprehensive enzyme discovery and enzyme, pathway and diversified strain engineering platform, bit-QED, to rapidly develop biobased products.
The CMO deal ensures that bitBiome is a fully integrated front- and back-end company, offering the full biomanufacturing workflow, from discovery and development to manufacture and supply.
“With this partnership, bitBiome has not only the access to the largest genetic repository from which new products and ingredients can be discovered and developed, but we now have the full capacity to manufacture and produce those products at commercial scale, making bitBiome a clear partner for companies looking to streamline the path from discovery to full-scale manufacturing all while reducing time and cost,” said CEO, Yuji Suzuki.